This review article examined the potential benefits and risks of NAD+ (nicotinamide adenine dinucleotide) therapeutic approaches, including NMN supplementation, across age-related degenerative diseases by analyzing existing clinical and preclinical evidence. The authors assessed both the rationale for NAD+ augmentation in aging-related conditions and identified potential safety concerns requiring consideration in therapeutic development. This is a **review article** synthesizing existing human clinical, animal model, and in vitro research rather than original research data.